FDA Should Create Oversight Body For Consumer Rx Information, Cmte Says
Executive Summary
FDA should create an oversight group with enforcement authority to ensure that privately distributed consumer drug information complies with "usefulness" criteria, FDA's Drug Safety & Risk Management Advisory Committee recommended July 17
You may also be interested in...
FDA Risk Communication Advisory Cmte. Will Assess Pharmacy Leaflets’ Utility
FDA's Risk Communication Advisory Committee will meet Feb. 26-27 to discuss how to improve the usability of consumer medical information leaflets distributed by pharmacies with prescription drugs
FDA Risk Communication Advisory Cmte. Will Assess Pharmacy Leaflets’ Utility
FDA's Risk Communication Advisory Committee will meet Feb. 26-27 to discuss how to improve the usability of consumer medical information leaflets distributed by pharmacies with prescription drugs
Patient Rx Info Coalition Will Develop Prototype Consumer Drug Leaflets
The private-sector Consumer Medicine Information Coalition plans to develop prototypes for written patient prescription information by therapeutic class